Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPLE-HCM: Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy
NCT05767346Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Jun 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Started Jun 2023; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05767346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767346.